Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Plus Therapeutics (PSTV) Other Operating Expenses (2016 - 2023)

Plus Therapeutics has reported Other Operating Expenses over the past 13 years, most recently at $2.7 million for Q4 2023.

  • Quarterly Other Operating Expenses rose 15005.56% to $2.7 million in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $2.7 million through Sep 2024, up 16893.75% year-over-year, with the annual reading at -$66000.0 for FY2021, N/A changed from the prior year.
  • Other Operating Expenses was $2.7 million for Q4 2023 at Plus Therapeutics, up from -$2000.0 in the prior quarter.
  • Over five years, Other Operating Expenses peaked at $2.7 million in Q4 2023 and troughed at -$305000.0 in Q4 2019.
  • The 5-year median for Other Operating Expenses is $94000.0 (2019), against an average of $388666.7.
  • Year-over-year, Other Operating Expenses tumbled 748.94% in 2019 and then surged 15005.56% in 2023.
  • A 5-year view of Other Operating Expenses shows it stood at -$305000.0 in 2019, then surged by 356.07% to $781000.0 in 2020, then crashed by 102.3% to -$18000.0 in 2021, then skyrocketed by 200.0% to $18000.0 in 2022, then surged by 15005.56% to $2.7 million in 2023.
  • Per Business Quant, the three most recent readings for PSTV's Other Operating Expenses are $2.7 million (Q4 2023), -$2000.0 (Q1 2023), and $18000.0 (Q4 2022).